DUAL-PATHWAY BLOCKADE THERAPY OFFERS HOPE FOR RARE, HARD-TO-TREAT GYNAECOLOGICAL CLEAR CELL CANCERS

B International study demonstrates promising clinical activity of pembrolizumab plus lenvatinib in recurrent disease, addressing a longstanding treatment gap SINGAPORE, April 23, 2026 /PRNewswire/ — Before…
posteditor
posteditor
Articles: 17424

Other News